Helsinn closes financing agreement with Oberland Capital
Helsinn closes financing agreement with Oberland Capital
- Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisition
- Dr Melanie Rolli recently appointed to lead and execute on Helsinn’s strategy
Lugano, Switzerland, January 10, 2023 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, following the announcement of the newly appointed CEO, Dr Melanie Rolli, today announces a financing agreement with Oberland Capital Management LLC (“Oberland Capital”).
Guided by its core values of respect, integrity and quality, Helsinn’s strategy focuses on being the partner of choice as a commercial-stage enterprise with a strong focus in oncology and rare diseases, able to reach patients worldwide through its integrated CMC/manufacturing/supply and commercial platform complemented by scientific and technological expertise.
Riccardo Braglia, Executive Chairman of Helsinn, commented: “Helsinn has partnership agreements with over 40 long-standing partners worldwide in 190 countries, and is a partner of choice for the biotech and pharma sector due to its expertise and late-stage development and commercialization of oncology and rare disease products. With its strong position which supports the integrated CMC, manufacturing, supply and commercial platform complemented by scientific and technical expertise, Helsinn is positioned to get more products to patients worldwide.”
Dr Melanie Rolli, recently appointed Chief Executive Officer at Helsinn, said: “I am pleased that we have secured this funding from Oberland Capital which will allow us toexpand the portfolio of late- and commercial-stage oncology and rare disease products. With an underlying stable business and this additional financial strength, we are well positioned to identify and partner with companies that share our focus on extending and improving the lives of people with cancer all over the world.”
William Clifford, Partner at Oberland Capital added: “We are excited to partner with Helsinn and support its strategy of in-licensing or acquiring oncology and rare disease products that address unmet medical needs. Our flexible investment structure is designed to enable Helsinn to expand its robust commercial platform and to generate significant operating leverage.”
About Oberland Capital
Oberland Capital is a private investment firm formed in 2013 with assets under management in excess of $3 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners. Oberland Capital’s broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners.
For more information, please visit www.oberlandcapital.com.
Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.
Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn’s unique business model enables it to in-license or acquire assets at a late stage of development. It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd.
Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.
To learn more about Helsinn please visit www.helsinn.com
For more information:
Helsinn Media Contact:
Group Head of Communication
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.comand follow us on TwitterandLinkedIn
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notification of managers and closely related parties’ transactions with A.P. Møller - Mærsk A/S shares in connection with share buy-back program29.3.2023 08:50:55 CEST | Press release
In connection with the announced share buy-back program in A.P. Møller - Mærsk A/S, A.P. Møller Holding A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Attachment APMM Share buy-back APMH sale 28032023
Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med A.P. Møller - Mærsk A/S aktier i forbindelse med aktietilbagekøbsprogram29.3.2023 08:50:55 CEST | pressemeddelelse
I forbindelse med det annoncerede aktietilbagekøbsprogram i A.P. Møller - Mærsk A/S sælger A.P. Møller Holding A/S løbende aktier pro rata og markedet informeres følgeligt herom - se vedhæftede fil. Vedhæftet fil APMM Aktietilbagekøbsprogram APMH salg_28032023
Transactions by persons discharging managerial responsibilities29.3.2023 08:45:00 CEST | Press release
Company Announcement no. 122– 2023 Copenhagen, March29th, 2023 Transactions by persons discharging managerial responsibilities Pursuant to the EU Market Abuse Regulation, GreenMobility A/S hereby reports transactions made in GreenMobility A/S shares by persons obliged to report on transactions to the Danish FSA and Nasdaq Copenhagen Main Market. Tue Østergaard, Chairman of the board, has purchased 57 shares in GreenMobility A/S, resulting in a total holding of 16,050 shares For further details, please refer to the attached forms for notification and public disclosure of transactions performed by persons with managerial responsibilities and persons closely associated with them. Contact and further information Anders Wall, Group CFO, +45 25 40 30 20, e-mail: email@example.com About GreenMobility GreenMobility offers modern urbanites easy, flexible, and sustainable transport in the form of electric shared city cars. Users have access to these cars via the GreenMobility app. Trips are p
Invitation Annual General Meeting Fenix Outdoor International AG29.3.2023 08:30:00 CEST | Press release
Invitation to the ordinary General Meeting of Shareholders of Fenix Outdoor International AG Dear Shareholder, The Board of Directors is pleased to invite you to the ordinary General Meeting concerning the financial year 2022 Date: Friday, April 21 2023, 2 pm Place: Hemvärnsgatan 9, Solna (Sweden) I. Notification Shareholders who wish to attend (in person, representation by proxy or by the Independent Proxy) the ordinary General Meeting must be recorded in the Company's share register by Thursday, 13 April 2023 at the latest and must notify the Company no later than Tuesday, 18 April 2023, 1 p.m. by telephone +46 660 26 62 00, by mail to Fenix Outdoor International AG, Hemvärnsgatan 15, 171 54 Solna (Sweden) or by e-mail firstname.lastname@example.org of their attendance. An e-mail from the Company confirming the receipt of the notification must be presented at the entrance in order to be admitted to the ordinary General Meeting. The notification of the Shareholder must include name, personal id
Fenix Outdoor International AG Kallelse Årsstämma29.3.2023 08:30:00 CEST | Pressemelding
Kallelse till årsstämma för aktieägarei Fenix Outdoor International AG Kära aktieägare, Styrelsen inbjuder er härmed till årsstämma för räkenskapsåret 2022. Datum: Fredagen den 21 april 2023, kl. 14:00 Place: Hemvärnsgatan 9, Solna (Sverige) I. Anmälan Aktieägare som önskar att delta (personligen, genom ombud eller genom det oberoende ombudet) på årsstämman måste vara införd i bolagets aktiebok senast torsdagen den 13 april 2023 och anmäla sitt deltagande till bolaget senast tisdagen den 18 april 2023 kl. 13 00 på telefon +46 660 26 62 00, per post till Fenix Outdoor International AG, Hemvärnsgatan 15, 171 54 Solna, Sverige eller genom e-mail till email@example.com. Ett e-mail från bolaget som bekräftar mottagande av anmälan, måste uppvisas vid entrén för tillträde till årsstämman. Aktieägarens anmälan måste innehålla namn, personnummer (organisationsnummer), adress, e-postadress (om tillämpligt), telefonnummer och namnet på eventuella medföljande biträden. Aktieägare som har sina a